179 related articles for article (PubMed ID: 37813883)
1. Joint analysis of the metabolomics and transcriptomics uncovers the dysregulated network and develops the diagnostic model of high-risk neuroblastoma.
Du B; Zhang F; Zhou Q; Cheng W; Yu Z; Li L; Yang J; Zhang X; Zhou C; Zhang W
Sci Rep; 2023 Oct; 13(1):16991. PubMed ID: 37813883
[TBL] [Abstract][Full Text] [Related]
2. Metabolomics-transcriptomics joint analysis: unveiling the dysregulated cell death network and developing a diagnostic model for high-grade neuroblastoma.
Zhang W; Zhang M; Sun M; Hu M; Yu M; Sun J; Zhang X; Du B
Front Immunol; 2023; 14():1345734. PubMed ID: 38239355
[TBL] [Abstract][Full Text] [Related]
3. A Pilot Study on the Utility of Serum Metabolomics in Neuroblastoma Patients and Xenograft Models.
Beaudry P; Campbell M; Dang NH; Wen J; Blote K; Weljie AM
Pediatr Blood Cancer; 2016 Feb; 63(2):214-20. PubMed ID: 26481088
[TBL] [Abstract][Full Text] [Related]
4. Incorporating genomic, transcriptomic and clinical data: a prognostic and stem cell-like MYC and PRC imbalance in high-risk neuroblastoma.
Yang XH; Tang F; Shin J; Cunningham JM
BMC Syst Biol; 2017 Oct; 11(Suppl 5):92. PubMed ID: 28984200
[TBL] [Abstract][Full Text] [Related]
5. Metabolomic profiling in neuroblastoma.
Quintás G; Yáñez Y; Gargallo P; Juan Ribelles A; Cañete A; Castel V; Segura V
Pediatr Blood Cancer; 2020 Mar; 67(3):e28113. PubMed ID: 31802629
[TBL] [Abstract][Full Text] [Related]
6. A c-Myc-regulated stem cell-like signature in high-risk neuroblastoma: A systematic discovery (Target neuroblastoma ESC-like signature).
Yang XH; Tang F; Shin J; Cunningham JM
Sci Rep; 2017 Mar; 7(1):41. PubMed ID: 28246384
[TBL] [Abstract][Full Text] [Related]
7. Distinct Expression Profiles of Neuroblastoma-Associated mRNAs in Peripheral Blood and Bone Marrow of Non-High-Risk and High-Risk Neuroblastoma Patients.
Nakatani N; Win KHN; Mon CY; Fujikawa T; Uemura S; Saito A; Ishida T; Mori T; Hasegawa D; Kosaka Y; Inoue S; Nishimura A; Nino N; Tamura A; Yamamoto N; Nozu K; Nishimura N
Biology (Basel); 2024 May; 13(5):. PubMed ID: 38785826
[TBL] [Abstract][Full Text] [Related]
8. [A comprehensive analysis of potential prognostic biomarkers for MYCN-amplified neuroblastoma].
Fan X; Lu HT; Hou L; Zhang L; Yang BY; Chen WM; Zhang HY; Chen X; Li FJ
Zhongguo Dang Dai Er Ke Za Zhi; 2020 Mar; 22(3):262-268. PubMed ID: 32204764
[TBL] [Abstract][Full Text] [Related]
9. [Plasma metabolomics in a deep vein thrombosis rat model based on ultra-high performance liquid chromatography-electrostatic field orbitrap high resolution mass spectrometry].
Gu Y; Zang P; Li J; Yan Y; Wang J
Se Pu; 2022 Aug; 40(8):736-745. PubMed ID: 35903841
[TBL] [Abstract][Full Text] [Related]
10. Expression Patterns of Immune Genes Reveal Heterogeneous Subtypes of High-Risk Neuroblastoma.
Liu Z; Grant CN; Sun L; Miller BA; Spiegelman VS; Wang HG
Cancers (Basel); 2020 Jun; 12(7):. PubMed ID: 32629858
[TBL] [Abstract][Full Text] [Related]
11. Integrated analysis of the functions and prognostic values of RNA-binding proteins in neuroblastoma.
Yang J; Zhou J; Li C; Wang S
PLoS One; 2021; 16(12):e0260876. PubMed ID: 34879089
[TBL] [Abstract][Full Text] [Related]
12. Serum-circulating miRNAs predict neuroblastoma progression in mouse model of high-risk metastatic disease.
Ramraj SK; Aravindan S; Somasundaram DB; Herman TS; Natarajan M; Aravindan N
Oncotarget; 2016 Apr; 7(14):18605-19. PubMed ID: 26921195
[TBL] [Abstract][Full Text] [Related]
13. Co-expression analysis identifies long noncoding RNA SNHG1 as a novel predictor for event-free survival in neuroblastoma.
Sahu D; Hsu CL; Lin CC; Yang TW; Hsu WM; Ho SY; Juan HF; Huang HC
Oncotarget; 2016 Sep; 7(36):58022-58037. PubMed ID: 27517149
[TBL] [Abstract][Full Text] [Related]
14. Dynamic alterations of plasma cell free DNA in response to chemotherapy in children with neuroblastoma.
Su Y; Wang L; Wang X; Yue Z; Xing T; Zhao W; Zhao Q; Duan C; Huang C; Han Y; Qiu L; Cheng X; Liu Y; Ma X
Cancer Med; 2019 Apr; 8(4):1558-1566. PubMed ID: 30793512
[TBL] [Abstract][Full Text] [Related]
15. Combined analysis of RNA-sequence and microarray data reveals effective metabolism-based prognostic signature for neuroblastoma.
Meng X; Feng C; Fang E; Feng J; Zhao X
J Cell Mol Med; 2020 Sep; 24(18):10367-10381. PubMed ID: 32683778
[TBL] [Abstract][Full Text] [Related]
16. Plasma-Derived Exosome Proteins as Novel Diagnostic and Prognostic Biomarkers in Neuroblastoma Patients.
Morini M; Raggi F; Bartolucci M; Petretto A; Ardito M; Rossi C; Segalerba D; Garaventa A; Eva A; Cangelosi D; Bosco MC
Cells; 2023 Oct; 12(21):. PubMed ID: 37947594
[TBL] [Abstract][Full Text] [Related]
17. A novel clinical tool and risk stratification system for predicting the event-free survival of neuroblastoma patients: A TARGET-based study.
Li M; Duan X; Li C; You D; Liu L
Medicine (Baltimore); 2023 Sep; 102(38):e34925. PubMed ID: 37746942
[TBL] [Abstract][Full Text] [Related]
18. Genomic profile of MYCN non-amplified neuroblastoma and potential for immunotherapeutic strategies in neuroblastoma.
Lee E; Lee JW; Lee B; Park K; Shim J; Yoo KH; Koo HH; Sung KW; Park WY
BMC Med Genomics; 2020 Nov; 13(1):171. PubMed ID: 33172452
[TBL] [Abstract][Full Text] [Related]
19. A nomogram for predicting recurrence-free survival of intermediate and high-risk neuroblastoma.
Sun Q; Chen Y; Jin Q; Yuan X
Eur J Pediatr; 2022 Dec; 181(12):4135-4147. PubMed ID: 36149505
[TBL] [Abstract][Full Text] [Related]
20. A Retrospective Analysis of the Therapeutic Outcomes of 117 Neuroblastoma Patients Treated at a Single Pediatric Oncology Center in China.
Yu U; Xu H; Chen S; Yi M; Liu C; Zhang X; Wang C; Song J; Gan Y; Wang J; Wang Y; Zhang Q; Sun J; Xia B; Zhang G; Li C; Wen F; Liu S; Yuan X
Cancer Control; 2023; 30():10732748231187837. PubMed ID: 37575028
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
